about
Clinical association analysis of ependymomas and pilocytic astrocytomas reveals elevated FGFR3 and FGFR1 expression in aggressive ependymomas.Circulating mutational portrait of cancer: manifestation of aggressive clonal events in both early and late stages.Vipie: web pipeline for parallel characterization of viral populations from multiple NGS samples.Microseminoprotein-Beta Expression in Different Stages of Prostate Cancer.Virtual cell imaging: A review on simulation methods employed in image cytometry.Integrated RNA-seq and DNase-seq analyses identify phenotype-specific BMP4 signaling in breast cancer.Segmentum: a tool for copy number analysis of cancer genomes.Feature-based analysis of mouse prostatic intraepithelial neoplasia in histological tissue sections.Integrated clinical, whole-genome, and transcriptome analysis of multisampled lethal metastatic prostate cancer.Myeloid cell expressed proprotein convertase FURIN attenuates inflammation.Analysis of spatial heterogeneity in normal epithelium and preneoplastic alterations in mouse prostate tumor models.Assessment of PARP protein expression in epithelial ovarian cancer by ELISA pharmacodynamic assay and immunohistochemistry.Comparative analysis of osteoblast gene expression profiles and Runx2 genomic occupancy of mouse and human osteoblasts in vitro.Androgen Receptor Deregulation Drives Bromodomain-Mediated Chromatin Alterations in Prostate Cancer.Overexpression of PTP4A3 in ETV6-RUNX1 acute lymphoblastic leukemia.RNA Polymerase III Subunit POLR3G Regulates Specific Subsets of PolyA+ and SmallRNA Transcriptomes and Splicing in Human Pluripotent Stem Cells.Whole-exome sequencing of Finnish hereditary breast cancer families.Metastasis detection from whole slide images using local features and random forests.Strong FGFR3 staining is a marker for FGFR3 fusions in diffuse gliomas.Genome-wide repression of eRNA and target gene loci by the ETV6-RUNX1 fusion in acute leukemia.Oncogenic K-Ras upregulates ITGA6 expression via FOSL1 to induce anoikis resistance and synergizes with αV-Class integrins to promote EMT.Concordance of Circulating Tumor DNA and Matched Metastatic Tissue Biopsy in Prostate Cancer.Treatment Outcomes and Tumor Loss of Heterozygosity in Germline DNA Repair-deficient Prostate Cancer.The expression of AURKA is androgen regulated in castration-resistant prostate cancer.Laminin α5 substrates promote survival, network formation and functional development of human pluripotent stem cell-derived neurons in vitro.Topical fluorometholone treatment and desiccating stress change inflammatory protein expression in tears.Feasibility of Prostate PAXgene Fixation for Molecular Research and Diagnostic Surgical Pathology: Comparison of Matched Fresh Frozen, FFPE, and PFPE Tissues.Circulating tumor DNA genomics correlate with resistance to abiraterone and enzalutamide in prostate cancer.NRF2, DJ1 and SNRX1 and their prognostic impact in astrocytic gliomas.Circulating Tumor DNA Reveals Clinically Actionable Somatic Genome of Metastatic Bladder Cancer.Chromatin accessibility is associated with CRISPR-Cas9 efficiency in the zebrafish (Danio rerio).Comparative Analysis of Tissue Reconstruction Algorithms for 3D Histology.Expressional profiling of prostate cancer risk SNPs at 11q13.5 identifies DGAT2 as a new target gene.Genomic Alterations in Cell-Free DNA and Enzalutamide Resistance in Castration-Resistant Prostate Cancer.Driver Fusions and Their Implications in the Development and Treatment of Human Cancers.Whole-exome sequencing identifies germline mutation in TP53 and ATRX in a child with genomically aberrant AT/RT and her mother with anaplastic astrocytoma.Integrative proteomics in prostate cancer uncovers robustness against genomic and transcriptomic aberrations during disease progression.Erratum: Whole-exome sequencing identifies germline mutation in TP53 and ATRX in a child with genomically aberrant AT/RT and her mother with anaplastic astrocytoma.Frequent mutation of the untranslated region in prostate cancerComputational Characterization of Suppressive Immune Microenvironments in Glioblastoma
P50
Q33634701-3A9A4841-D45E-456C-8BD4-7CFCACF67BEEQ33640472-9435EF4B-AC7D-4199-BC21-6EE25CC3F868Q33681785-C472B7B3-3C6E-48D0-A2BF-7B79BB21D8CBQ35944835-D75D50D9-8A0A-42DA-9C6F-6CFDA2B08BA1Q36214155-41662D33-4E54-43F5-A06E-6FD4A7EE9C4CQ36246637-0A1CF4C2-3201-4EFA-A43B-8EE92C7AD814Q36346318-398A8AAB-5051-4317-8D49-F33F8520A4FEQ36606721-281B4F7F-27F5-4EC1-AACB-C25753F7711BQ36859396-B9AD45B4-D23C-4766-B8B1-7FFFF628048DQ37688070-1C64AD32-5202-4F0C-AF55-86D8387532B0Q37710893-5E3A5A98-74C2-46B7-A17C-E0156A18F84FQ38377713-AF5721DE-3E4C-427C-AFF8-ADE2F1C71BCBQ38433587-34078A04-B301-4AB2-8460-66C42710D026Q38673660-BF546D03-15A2-4E3D-A204-C3446B759BA2Q38722510-70C93BF8-B840-4836-9D24-091B7F7F4443Q38791523-86BD6F6F-CBBB-4A6A-87A2-573DEC8B8D67Q38805455-52AA2B4B-29B7-4940-9235-0ED4B2E4D629Q40462406-1B182A95-842C-4CB6-ACAE-D23D9A51E39FQ41511970-66010257-ABBF-4030-9C1D-7B5C925437B6Q41634601-54149899-4B1E-4217-895C-35D7051408A3Q42619130-F84D7643-05EB-4A9B-ACFA-2A0D6E2CDC62Q46086455-6A0F576E-FA74-4CF2-8485-BB92B0A8E771Q46209531-E934D6D6-B90C-430F-861C-B7536C49E538Q47096576-C658AF5B-291A-44C5-8838-F72DA3E3E88EQ47778783-F3830270-492E-46A6-88A3-78A8F6FD4A61Q47791389-F84A3509-B923-4633-9586-C51E4C3C4C57Q49562114-2168A5ED-5F3C-4215-A276-7AE0CB630F13Q49790156-F9D0E702-E89E-4E3E-8C27-615C117ED412Q50020925-76A99CC1-D90A-4B54-9AA9-8C2790BB5966Q50515553-07191F66-2300-43F4-9169-5BD600706BF7Q52431777-6B777B42-D7D4-47BB-B62F-3331DC67D617Q52570038-95A96B08-CC99-439B-ADF0-8900BBCEA0CFQ53779715-6465D2A4-1F77-4E0B-9927-4C0660FE4A9DQ53787362-020273A0-9B7F-42FD-9A7C-DF2628DE7017Q54117733-B16B9189-B4A7-4A59-9940-DA2FF4D98544Q54958675-E1D69446-84C9-473E-8DFB-2BADAC0935E5Q55082840-9E0F1AD7-0B8E-4498-8F5B-3D38D08AF8CEQ55397697-81465FD9-E78F-4EA1-86CB-82299F76AC3FQ57132120-3D429524-782D-4FE2-B20C-64E83477B1CAQ57135357-0A0112BC-F83B-47B3-8A06-53031AEE6511
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Matti Nykter
@ast
Matti Nykter
@en
Matti Nykter
@es
Matti Nykter
@fr
Matti Nykter
@nl
Matti Nykter
@sl
type
label
Matti Nykter
@ast
Matti Nykter
@en
Matti Nykter
@es
Matti Nykter
@fr
Matti Nykter
@nl
Matti Nykter
@sl
prefLabel
Matti Nykter
@ast
Matti Nykter
@en
Matti Nykter
@es
Matti Nykter
@fr
Matti Nykter
@nl
Matti Nykter
@sl
P106
P21
P31
P496
0000-0001-6956-2843